Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

PHASE4CompletedINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
DRUG

BG00012 (DMF)

Trial Locations (37)

11772

Research Site, Patchogue

15215

Research Site, Monroeville

23298

Research Site, Richmond

24018

Research Site, Roanoke

27262

Research Site, High Point

27405

Research Site, Greensboro

28204

Research Site, Charlotte

30327

Research Site, Atlanta

32751

Research Site, Maitland

33408

Research Site, North Palm Beach

33609

Research Site, Tampa

33612

Research Site, Tampa

33713

Research Site, St. Petersburg

33952

Research Site, Port Charlotte

34102

Research Site, Naples

34239

Research Site, Sarasota

35058

Research Site, Cullman

37064

Research Site, Franklin

37934

Research Site, Knoxville

38018

Research Site, Cordova

46256

Research Site, Indianapolis

53215

Research Site, Milwaukee

55422

Research Site, Golden Valley

58103

Research Site, Fargo

78681

Research Site, Round Rock

80113

Research Site, Englewood

80528

Research Site, Fort Collins

84103

Research Site, Salt Lake City

85234

Research Site, Gilbert

85258

Research Site, Scottsdale

91105

Research Site, Pasadena

92663

Research Site, Newport Beach

92835

Research Site, Fullerton

97225

Research Site, Portland

98405

Research Site, Tacoma

06810

Research Site, Danbury

01757

Research Site, Milford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY